CBLB Antibody

說(shuō)明書(shū)

中文名稱：

CBLB兔多克隆抗體
貨號(hào)：

CSB-PA004579GA01HU
規(guī)格：

￥3,900
其他：

產(chǎn)品詳情
產(chǎn)品評(píng)價(jià)
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

Uniprot No.：

Q13191
基因名：

CBLB
別名：

CBLB antibody; RNF56 antibody; Nbla00127 antibody; E3 ubiquitin-protein ligase CBL-B antibody; EC 2.3.2.27 antibody; Casitas B-lineage lymphoma proto-oncogene b antibody; RING finger protein 56 antibody; RING-type E3 ubiquitin transferase CBL-B antibody; SH3-binding protein CBL-B antibody; Signal transduction protein CBL-B antibody
宿主：

Rabbit
反應(yīng)種屬：

Human,Mouse,Rat
免疫原：

Human CBLB
免疫原種屬：

Homo sapiens (Human)
抗體亞型：

IgG
純化方式：

Antigen Affinity Purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

PBS with 0.1% Sodium Azide, 50% Glycerol, pH 7.3. -20°C, Avoid freeze / thaw cycles.
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

ELISA,WB,IHC,IP
Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
Immunohistochemistry (IHC) Protocol
Immunoprecipitation (IP) Protocol
儲(chǔ)存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

功能：

E3 ubiquitin-protein ligase which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and transfers it to substrates, generally promoting their degradation by the proteasome. Negatively regulates TCR (T-cell receptor), BCR (B-cell receptor) and FCER1 (high affinity immunoglobulin epsilon receptor) signal transduction pathways. In naive T-cells, inhibits VAV1 activation upon TCR engagement and imposes a requirement for CD28 costimulation for proliferation and IL-2 production. Also acts by promoting PIK3R1/p85 ubiquitination, which impairs its recruitment to the TCR and subsequent activation. In activated T-cells, inhibits PLCG1 activation and calcium mobilization upon restimulation and promotes anergy. In B-cells, acts by ubiquitinating SYK and promoting its proteasomal degradation. Slightly promotes SRC ubiquitination. May be involved in EGFR ubiquitination and internalization. May be functionally coupled with the E2 ubiquitin-protein ligase UB2D3. In association with CBL, required for proper feedback inhibition of ciliary platelet-derived growth factor receptor-alpha (PDGFRA) signaling pathway via ubiquitination and internalization of PDGFRA.
基因功能參考文獻(xiàn)：
1. This study aimed to investigate the difference between the expression of Cbl-b in lung squamous cell carcinoma and adenocarcinoma. PMID: 29384143
2. miR-891b regulated the Smad3/ p21 axis by directly targeting the Cbl-b gene to inhibit the proliferative ability of pancreatic adenocarcinoma cells. PMID: 27494897
3. our findings suggest that E3 ubiquitin ligase Cbl-b modulates the interplay between effector and Tregs, particularly resistance to the suppression phenotype by regulating the K63 polyubiquitination profile in lupus Tregs. PMID: 28940360
4. These results suggest that Cbl-b is an important factor for maintenance of the epithelial phenotype and inhibition of cell migration in MDR gastric and breast cancer cells. PMID: 28334634
5. Silencing CBLB in human monocyte-derived macrophages resulted in increased cytokine production and impaired down-modulation of dectin-1 and dectin-2 expression after C.albicans exposure. PMID: 27428899
6. this study shows that rs2305035 genotypes in CBLB are associated with clinical and radiation pneumonitis risk among patients with non-small-cell lung cancer treated with definitive radiotherapy PMID: 26732495
7. Results suggest that Cbl-b improves the prognosis of RANK-expressing breast cancer patients by inhibiting RANKL-induced breast cancer cell migration and metastasis. PMID: 26087197
8. direct interaction between Cblin and the TKB domain of Cbl-b PMID: 26874193
9. findings suggest that Cbl-b limits NGF-TrkA signaling to control the length of neurites. PMID: 25921289
10. Translocation of Cbl-b from the nucleus to the cytoplasm prevented the localization of P-gp to caveolae resulting in the reversal of multidrug resistance through the ubiquitination and degradation of c-Src. PMID: 25788263
11. Our results suggest that celecoxib-mediated upregulation of Cbl-b is responsible, at least in part, for the additive antitumor effect of celecoxib and rapamycin via inhibition of rapamycin-induced Akt activation. PMID: 25701378
12. results show that Cbl-b suppresses human ORMDL3 expression through STAT6 PMID: 26112603
13. Low CBLB expression is associated with glioma cell invasion. PMID: 25691332
14. The data suggest a role of the CBLB rs12487066 variant in the interactions of a genetic risk factor and IFN function during viral infections in multiple sclerosis. PMID: 25261476
15. Ubiquitin ligase Cbl-b represses IGF-I-induced epithelial mesenchymal transition via ZEB2 and microRNA-200c regulation in gastric cancer cells. PMID: 24885194
16. Cbl-b knockdown caused significant increase of phosphorylation of EGFR, ERK and Akt, decrease of mitochondrial membrane potential, and increase of expression ratio of Bcl-2/Bax. PMID: 24351824
17. that icotinib-induced upregulation of Cbl-b is responsible, at least in part, for the antitumor effect of icotinib via the inhibition of phosphoinositide 3-kinase (PI3K)/Akt and mitogen-activated protein kinase pathways in EGFR-mutated NSCLC cells. PMID: 23586056
18. abnormal peripheral tolerance in SLE is caused by a deficiency in Cbl-b, and that this ubiquitin ligase plays a key role in regulating T-cell receptor signaling during the induction of peripheral tolerance. PMID: 23280105
19. FOXP3 mRNA expression correlated with CBLB and ITCH in MS patients. PMID: 23039885
20. Pooled analysis corroborated the effect on multiple sclerosis predisposition of three genes: TMEM39A, IL12B, and CBLB PMID: 22194214
21. Data show that bufalin-induced down-regulation of Cbl-b contributed to the up-regulation of TRAIL Receptors DR4 and DR5. PMID: 22447040
22. Autoinhibition and phosphorylation-induced activation mechanisms of human cancer and autoimmune disease-related E3 protein Cbl-b PMID: 22158902
23. Over expression of TGF-beta and CTLA-4 leads to T cell hyporesponsiveness, a major hallmark of leprosy, by increasing the expression of Cbl-b. PMID: 21807564
24. data suggest that Cbl-b may contribute to the deregulated activation of T lymphocytes observed in systemic lupus erythematosus (SLE); a significant association between the 2126(A/G) SNP and SLE was detected PMID: 21558139
25. CBLB mutation is asssociated with chronic myelogenous leukemia. PMID: 21346257
26. Deregulations of Lck-ZAP-70-Cbl-b cross-talk and miR181a in T cells were found to be associated with cholesterol-dependent-dismantling of HLA-DR rafts in macrophages in leprosy progression. PMID: 21453975
27. These data provide further evidence of the association of MS disease with variation within CBLB. PMID: 21037273
28. Interplay between transgenic Cblb-dependent T cell anergy and other mechanisms prevents organ-specific islet-cell autoimmunity. PMID: 21248249
29. Cbl-b plays a positive modulatory role in GPVI-dependent platelet signaling, which translates to an important regulatory role in hemostasis and thrombosis in vivo PMID: 20400514
30. Cbl-b and itch are key regulators of peripheral T-cell tolerance [review] PMID: 20395198
31. Cbl-b plays a negative role in Crk-L-C3G-mediated Rap1 and LFA-1 activation in T cells. PMID: 12697763
32. Expression of Cbl-b effectively blocks the ability of Cool-2 to stimulate PAK, providing an additional mechanism, aside from catalyzing receptor ubiquitination, by which Cbl-b acts as a negative regulator for signaling activities requiring PAK activation. PMID: 12935897
33. Cbl-b is a negative regulator of both Lyn-Syk-LAT and Gab2mediated complementary signaling pathways in FcepsilonRI-mediated mast cell activation PMID: 14604964
34. genetic interaction between the CTLA4 and CBLB genes in type 1 diabetes PMID: 15629882
35. NF-kappaB activity is enhanced by a PI3K signal mediated by Cbl-b and Rho PMID: 15922296
36. results suggest that Cbl-b- or atrogin-1-mediated ubiquitination plays an important role in unloading-induced muscle atrophy, and that unloading stress may preferentially inhibit transcriptional responses in skeletal muscle PMID: 16868939
37. In a primary analysis, no evidence for an association of the CBLB SNP rs3772534 with disease was found in either sample set in type 1 diabetes. PMID: 17209142
38. the host ubiquitin ligase Cbl-b interacts with the type III-secreted effector exotoxin T (ExoT) and plays a key role in vivo in limiting bacterial dissemination mediated by ExoT PMID: 17235393
39. F328L mutation is involved in the development of autoimmune diseases including type 1 diabetes, and also provide insight into the structure-function relationship of CBLB protein PMID: 18201552
40. Cbls suppress cell death in healthy neurons at least in part by inhibiting the ability of mixed lineage kinases to activate JNK signaling. PMID: 19546888
顯示更多

收起更多
亞細(xì)胞定位：

Cytoplasm. Note=Upon EGF stimulation, associates with endocytic vesicles.
組織特異性：

Expressed in placenta, heart, lung, kidney, spleen, ovary and testis, as well as fetal brain and liver and hematopoietic cell lines, but not in adult brain, liver, pancreas, salivary gland, or skeletal muscle. Present in lymphocytes (at protein level).
數(shù)據(jù)庫(kù)鏈接：

HGNC: 1542

OMIM: 604491

KEGG: hsa:868

STRING: 9606.ENSP00000264122

UniGene: Hs.430589

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human